Advertisement
NERV vs RLMD
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NERV is a Hold and RLMD is a Hold.
NERV's RSI Indicator ascending out of oversold territory
The RSI Indicator for NERV moved out of oversold territory on October 30, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 28 similar instances when the indicator left oversold territory. In 24 of the 28 cases the stock moved higher. This puts the odds of a move higher at 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on NERV as a result. In 59 of 74 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for NERV just turned positive on October 28, 2026. Looking at past instances where NERV's MACD turned positive, the stock continued to rise in 32 of 40 cases over the following month. The odds of a continued upward trend are 80%.
Following a +14.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where NERV advanced for three days, in 192 of 240 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NERV declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
NERV broke above its upper Bollinger Band on November 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for NERV entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.542) is normal, around the industry mean (3.498). P/E Ratio (-0.067) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.160) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. NERV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NERV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
RLMD in upward trend: price rose above 50-day moving average on November 06, 2026
RLMD moved above its 50-day moving average on November 06, 2026 date and that indicates a change from a downward trend to an upward trend. In 31 of 35 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 28, 2026. You may want to consider a long position or call options on RLMD as a result. In 77 of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for RLMD just turned positive on October 20, 2026. Looking at past instances where RLMD's MACD turned positive, the stock continued to rise in 33 of 38 cases over the following month. The odds of a continued upward trend are 87%.
The 10-day moving average for RLMD crossed bullishly above the 50-day moving average on November 10, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 13 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 85%.
Following a +9.49% 3-day Advance, the price is estimated to grow further. Considering data from situations where RLMD advanced for three days, in 225 of 265 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The 10-day RSI Indicator for RLMD moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 26 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 84%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 59 cases where RLMD's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 78%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RLMD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
RLMD broke above its upper Bollinger Band on October 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for RLMD entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 20 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 28 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.014) is normal, around the industry mean (3.498). P/E Ratio (-4.286) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.120) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 46 (best 1 - 100 worst), indicating steady price growth. RLMD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RLMD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
NERV | RLMD | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 32 | 36 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 42 Fair valued | 28 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 98 | |
PRICE GROWTH RATING 1..100 | 83 | 46 | |
P/E GROWTH RATING 1..100 | 98 | 20 | |
SEASONALITY SCORE 1..100 | 50 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
RLMD's Valuation (28) in the null industry is in the same range as NERV (42) in the Biotechnology industry. This means that RLMD’s stock grew similarly to NERV’s over the last 12 months.
RLMD's Profit vs Risk Rating (100) in the null industry is in the same range as NERV (100) in the Biotechnology industry. This means that RLMD’s stock grew similarly to NERV’s over the last 12 months.
RLMD's SMR Rating (98) in the null industry is in the same range as NERV (100) in the Biotechnology industry. This means that RLMD’s stock grew similarly to NERV’s over the last 12 months.
RLMD's Price Growth Rating (46) in the null industry is somewhat better than the same rating for NERV (83) in the Biotechnology industry. This means that RLMD’s stock grew somewhat faster than NERV’s over the last 12 months.
RLMD's P/E Growth Rating (20) in the null industry is significantly better than the same rating for NERV (98) in the Biotechnology industry. This means that RLMD’s stock grew significantly faster than NERV’s over the last 12 months.
| NERV | RLMD | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 86% | 2 days ago 84% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 78% |
| Momentum ODDS (%) | 2 days ago 80% | 2 days ago 88% |
| MACD ODDS (%) | 2 days ago 80% | 2 days ago 87% |
| TrendWeek ODDS (%) | 2 days ago 82% | 2 days ago 86% |
| TrendMonth ODDS (%) | 2 days ago 86% | 2 days ago 86% |
| Advances ODDS (%) | 3 days ago 80% | 2 days ago 85% |
| Declines ODDS (%) | 17 days ago 87% | 7 days ago 85% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 90% |
| Aroon ODDS (%) | 2 days ago 87% | 2 days ago 79% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
NERV’s FA Score shows that 0 FA rating(s) are green while RLMD’s FA Score has 2 green FA rating(s).
- NERV’s FA Score: 0 green, 5 red.
- RLMD’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
NERV’s TA Score shows that 4 TA indicator(s) are bullish while RLMD’s TA Score has 5 bullish TA indicator(s).
- NERV’s TA Score: 4 bullish, 4 bearish.
- RLMD’s TA Score: 5 bullish, 5 bearish.
Price Growth
NERV (@Biotechnology) experienced а +5.96% price change this week, while RLMD (@Biotechnology) price change was 0.00% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
NERV is expected to report earnings on Mar 09, 2027.
RLMD is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
RLMD and
Correlation & Price change
A.I.dvisor indicates that over the last year, RLMD has been loosely correlated with XENE. These tickers have moved in lockstep 54% of the time. This A.I.-generated data suggests there is some statistical probability that if RLMD jumps, then XENE could also see price increases.
| Ticker / NAME | Correlation To RLMD | 1D Price Change % | ||
|---|---|---|---|---|
| RLMD | 100% | +3.14% | ||
| XENE - RLMD | 54% Loosely correlated | +2.32% | ||
| NERV - RLMD | 44% Loosely correlated | -5.32% | ||
| DNTH - RLMD | 44% Loosely correlated | -1.32% | ||
| SLDB - RLMD | 43% Loosely correlated | +2.14% | ||
| DYN - RLMD | 41% Loosely correlated | -3.76% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| TY | 34.06 | -0.24 | -0.70% |
| TRI-Continental Corp | |||
| CXSE | 32.58 | -0.24 | -0.72% |
| WisdomTree China ex-State-Owned Enterprises Fund (CXSE) | |||
| MDEV | 22.81 | -0.23 | -0.98% |
| First Trust Indxx Medical Devices ETF (MDEV) | |||
| HTEC | 44.98 | -0.76 | -1.67% |
| ROBO Global Healthcare Technology and Innovation ETF (HTEC) | |||
| KCOP | 19.84 | -0.78 | -3.80% |
| Kurv Copper & Mining Enhanced Income ETF (KCOP) | |||